NASDAQ AMRX opened at $3.47 on Friday. The company has a debt-to-equity ratio of 6.65, a quick ratio of 1.46 and a current ratio of 2.31. The company has a market cap of $1.05 billion, a price-to-earnings ratio of 173.50, a PEG ratio of 0.18 and a beta of 1.17. The stock’s 50 day moving average price is $3.95. Amneal Pharmaceuticals has a 52 week low of $3.08 and a 52 week high of $6.21.
Amneal Pharmaceuticals (NASDAQ:AMRX – Get Rating) last released its quarterly earnings data on Wednesday, May 4th. The company reported $0.10 EPS for the quarter, meeting the consensus estimate of $0.10. Amneal Pharmaceuticals had a net margin of 0.08% and a return on equity of 53.73%. The business had revenue of $497.63 million for the quarter, compared to the consensus estimate of $500.68 million. Analysts anticipate that Amneal Pharmaceuticals will post 0.74 EPS for the current year.
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
- Get a free copy of the StockNews.com research report on Amneal Pharmaceuticals (AMRX)
- Silicon Labs Stock is Falling to a Better Place
- The Institutional Tide Has Turned For Cisco Systems
- Don’t Bet On Cheaper Oil, Not Yet Anway
- A Reversal In The S&P 500 Is Confirmed
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.